2019. Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S53. DOI:https://doi.org/10.25251/skin.3.supp.53.